{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:06:07Z","timestamp":1772755567041,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.vaccine.2013.03.038","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T15:02:02Z","timestamp":1365260522000},"page":"2603-2609","source":"Crossref","is-referenced-by-count":35,"title":["Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation"],"prefix":"10.1016","volume":"31","author":[{"given":"Adwoa D.","family":"Bentsi-Enchill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Roehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.03.038_bib0005","series-title":"Dengue: guidelines for diagnosis, treatment, prevention and control","author":"WHO","year":"2009"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/bmb\/ldq019","article-title":"Dengue","volume":"95","author":"Whitehorn","year":"2010","journal-title":"Br Med Bull"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0015","unstructured":"WHO. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva: World Health Organization; 2011. WHO\/BS\/11.2159."},{"key":"10.1016\/j.vaccine.2013.03.038_bib0020","unstructured":"WHO. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva, World Health Organization. WHO\/BS\/11.2159, in press."},{"key":"10.1016\/j.vaccine.2013.03.038_bib0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.coi.2011.03.005","article-title":"Dengue vaccines: progress and challenges","volume":"23","author":"Coller","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0030","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1016\/j.vaccine.2011.07.017","article-title":"Next generation dengue vaccines: a review of candidates in preclinical development","volume":"29","author":"Schmitz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0035","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.chom.2008.08.004","article-title":"Structural Insights into the mechanisms of antibody-mediated neutralization of flavivirus Infection: implications for vaccine development","volume":"4","author":"Pierson","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0045","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1016\/j.vaccine.2011.07.022","article-title":"The pathogenesis of dengue","volume":"29","author":"Whitehorn","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0055","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QCO.0b013e32834a1b0b","article-title":"Critical issues in dengue vaccine development","volume":"24","author":"Thomas","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0060","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/S1020-49892002000400003","article-title":"Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks","volume":"11","author":"Guzm\u00e1n","year":"2002","journal-title":"Rev Panam Salud Publica"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0070","first-page":"301","article-title":"Immune enhancement of viral infection","volume":"31","author":"Halstead","year":"1982","journal-title":"Prog Allergy"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0080","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.146.1.201","article-title":"Dengue viruses and mononuclear phagocytes: infection enhancement by non-neutralizing antibody","volume":"146","author":"Halstead","year":"1977","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2008.10.086","article-title":"Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development","volume":"27","author":"Thomas","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0090","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0095","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/500949","article-title":"Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement","volume":"193","author":"Avirutnan","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0100","series-title":"Guidelines for the clinical evaluation of dengue vaccines in endemic areas","author":"WHO","year":"2008"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults","volume":"5","author":"Sun","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0110","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0120","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4269\/ajtmh.2011.10-0501","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants","volume":"85","author":"Watanaveeradej","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0130","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0135","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0140","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1473-3099(01)00171-2","article-title":"Dengue: an update","volume":"2","author":"Guzm\u00e1n","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4269\/ajtmh.2012.10-0670","article-title":"Capillary leakage in travelers with dengue infection: implications for pathogenesis","volume":"86","author":"Meltzer","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1201-9712(02)90072-X","article-title":"Effect of age on outcome of secondary dengue 2 infections","volume":"6","author":"Guzm\u00e1n","year":"2002","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0160","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4269\/ajtmh.2005.73.1063","article-title":"Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua","volume":"73","author":"Hammond","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4269\/ajtmh.2011.10-0476","article-title":"Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam","volume":"84","author":"Anders","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0170","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/ng.960","article-title":"Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1","volume":"43","author":"Khor","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0175","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1371\/journal.pntd.0000617","article-title":"Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006","volume":"4","author":"Fried","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0180","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/infdis\/jir014","article-title":"Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status","volume":"203","author":"Duyen","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0185","first-page":"40.035","article-title":"A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a prospective school-based cohort in Thailand","volume":"16S1","author":"Anderson","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0190","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1128\/JVI.79.9.5516-5528.2005","article-title":"Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys","volume":"79","author":"Blaney","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","article-title":"Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody","volume":"392","author":"Wahala","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0200","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0205","first-page":"5782","article-title":"The Gambia hepatitis intervention study","volume":"47","author":"The Gambia Hepatitis Study Group","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0210","unstructured":"Extended follow-up of young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls. http:\/\/ClinicalTrials.gov (NCT ID: NCT00867464) [accessed 28.05.12]."},{"key":"10.1016\/j.vaccine.2013.03.038_bib0215","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.vaccine.2006.09.019","article-title":"Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine","volume":"25","author":"Madhi","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0220","doi-asserted-by":"crossref","first-page":"A36","DOI":"10.1016\/j.vaccine.2011.09.120","article-title":"Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial","volume":"30S","author":"Cunliffe","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-6-54","article-title":"The stepped wedge trial design: a systematic review","volume":"6","author":"Brown","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0230","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.vaccine.2004.01.017","article-title":"Control without separate controls: evaluation of vaccine safety using case-only methods","volume":"22","author":"Farrington","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0235","series-title":"Global vaccine safety blueprint","author":"WHO","year":"2012"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2013.03.038_bib0240","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1038\/nrmicro2459","article-title":"Evaluation of diagnostic tests: Dengue","volume":"8","author":"Peeling","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.038_bib0245","doi-asserted-by":"crossref","first-page":"e1450","DOI":"10.1371\/journal.pntd.0001450","article-title":"Assessing the potential of a candidate dengue vaccine with mathematical modeling","volume":"6","author":"WHO-VMI Dengue Vaccine Modeling Group","year":"2012","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13003733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T01:14:40Z","timestamp":1562894080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13003733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":49,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0264410X13003733"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}